Neuroprotectants in stroke therapy

Abstract

Background: Over the past 10 years clinical trials aimed at finding suitable neuroprotectants against the debilitating effects of stroke have met with no success. Identifying novel neuroprotectants that can reverse the effects of stroke is becoming a challenge to both clinicians and scientists.

Objectives: This review focused on the current status on the topic and highlights some of the neuroprotectants that are worth examining or re-examining further.

Methods: Recent findings on the subject have been included.

Conclusion: Many neuroprotectants that have worked in preclinical evaluations have been found to be ineffective in clinical trials. Nevertheless, some of them are still considered to be worth re-examining. Non-coding small RNAs (riboregulators) as novel therapeutic leads have also been introduced in this review.